Savers Value Village (SVV) General Counsel Executes 20,000-Share Sale Under 10b5-1
Rhea-AI Filing Summary
Richard A. Medway, General Counsel of Savers Value Village, Inc. (SVV), reported transactions on 09/26/2025. He exercised or acquired 20,000 shares of common stock at an exercise price of $1.41 and simultaneously sold 20,000 shares under a 10b5-1 plan at a weighted average price of $13.6905 (execution prices ranged from $13.48 to $13.87). After these transactions the reporting person shows 0 shares of common stock directly owned.
Table II shows derivative holdings of options representing the right to purchase common stock at $1.41 with 364,256 shares underlying reported as beneficially owned. The filing notes that certain options are time-based (approximately 12%) and performance-based (approximately 88%), with vesting and performance conditions described for the 2019 grant.
Positive
- Sale executed under a 10b5-1 plan, indicating pre-arranged trading and reduced concerns about opportunistic timing
- Weighted average sale price disclosed ($13.6905) with price range ($13.48–$13.87) and offer to provide per-price details, enhancing transparency
- Detailed vesting disclosure for the 2019 option grant, including time-based (~12%) and performance-based (~88%) splits
Negative
- Reporting person holds 0 direct common shares after transactions, which reduces immediate insider equity alignment with shareholders
- Significant number of performance-based options (≈88%) remain subject to future conditions, creating uncertainty about eventual dilution timing
Insights
TL;DR: Insider exercised and sold the same number of shares via a 10b5-1 plan, retaining substantial option exposure.
Medway exercised or acquired 20,000 shares at a nominal exercise price of $1.41 and sold those 20,000 shares under a 10b5-1 plan at a weighted average of $13.6905, realizing monetization while recording zero direct common shares after the sale. The filing discloses 364,256 option-based shares outstanding to the reporting person, comprised of time- and performance-based grants from a 2019 plan. For investors this indicates insider liquidity activity without reduction in option-based upside exposure; the sale was pre-planned under a 10b5-1 arrangement and the weighted average sale price range is disclosed.
TL;DR: Transaction appears routine and compliant; sale executed under a pre-established 10b5-1 plan.
The report explicitly states the sale was made pursuant to a 10b5-1 plan adopted March 10, 2025, and provides the weighted average sale price range with an offer to supply per-price execution details to regulators or shareholders. The option grant details and vesting schedules from June 12, 2019 are disclosed, including the split between time-based and performance-based awards. This level of disclosure supports compliance and transparency around insider trades and option vesting conditions.